SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.

BioAffinity Technologies Inc

BioAffinity Technologies ($BIAF) is trending due to new case studies highlighting the effectiveness of its CyPath Lung test for early lung cancer detection, with potential to reduce unnecessary biopsies. The community is actively discussing the stock's low float, potential for a short squeeze, and possible price targets. Interest is also driven by the company's focus on lung cancer, a significant health concern, and its potential impact on personalized care.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

Iris Energy Ltd

IREN is trending due to bullish sentiment around its AI data center business, despite some community members noting a recent pullback in the energy sector and analyst downgrades. Some traders are discussing the potential for a short squeeze, while others point to the stock's long-term potential in the AI space. Community members are actively debating recent price action and future price targets.

BTQ Technologies Corp

BTQQF is trending due to community discussions around its Nasdaq uplisting, the potential for increased exposure, and the shift to the new ticker symbol BTQ. Concerns about potential dilution and price manipulation are being weighed against bullish sentiment regarding the company's position in the quantum cybersecurity space and a possible upcoming 

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as investors weigh the impact of potential government funding changes and a possible government shutdown on the company's operations. Community discussions revolve around technical analysis, potential short squeezes, and the strategic importance of rare earth elements for national security. Some are concerned about rumors of pulled funding while others see the dip as a buying opportunity, emphasizing the company's critical role in the U.S. supply chain and national security.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending due to a newly announced deal with Fluidstack and backing from Google, with the community actively discussing the implications of the partnership and a related offering. Community members are focused on the potential for significant growth and a possible gamma squeeze, while also noting the company's commitment to avoiding dilution. The broader context involves Cipher's expansion into AI data centers and high-performance computing.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending due to a recently announced expansion of their partnership with OpenAI, valued at billions, driving bullish sentiment among investors. The community is actively discussing potential price targets and anticipating a continued upward trajectory, while some caution about debt and market volatility. The stock is closely tied to the AI sector and Nvidia, with mentions of potential short squeezes and long-term growth prospects.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE.X is trending as the community rallies around the meme coin, expressing bullish sentiment and urging others to join before a potential surge. Many reference a strong community and influential backers as reasons for the coin's potential. The coin is also gaining attention as a trending topic on UpDog.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals is trending due to the FDA approval of Palsonify, a once-daily oral drug for acromegaly, with anticipation building for its market availability in early October. Community members are discussing the potential for significant sales and a possible short squeeze, as well as analyst price target upgrades. Despite recent gains, some traders believe the stock is undervalued given its pipeline and potential expansion into Europe.

LightPath Technologies, Inc. engages in the design, development, manufacture, and distribution of optical and infrared components. Its products include molded glass and assemblies, infrared molded lenses, diamond turned, conventional ground and polished ground lenses and assemblies, and collimator assemblies, which are used in applications involving light detection and ranging technology. The firm supports a range of customers in the field of industrial, laser, defense, medical, telecommunications, and instrumentation. The company was founded on June 15, 1992 and is headquartered in Orlando, FL.

Lightpath Technologies, Inc. - Ordinary Shares - Class A

LPTH is trending due to analyst upgrades and excitement around potential defense contracts, particularly related to Lockheed Martin's missile program, with the community actively discussing its unique Black Diamond glass technology as a replacement for germanium. Investors are also highlighting the company's expansion into commercial applications and expressing optimism about its growth potential in 2025. Recent news and increasing investor interest are driving volatility, with some anticipating a significant move upwards.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending following the launch of its NikeSKIMS collaboration, a key part of their "Win Now" strategy to boost sales, particularly among female consumers; the community is actively discussing the launch, noting that some items are already sold out, and debating its potential impact on competitors like Lululemon. Despite the buzz around the new partnership, some analysts remain cautious about its immediate financial impact amid broader concerns about Nike's sales and ongoing challenges in the sportswear market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of bioAffinity Technologies (BIAF) soared 79% on Friday after the company released three additional case studies, including one in which the use of its CyPath Lung test led to the detection of lung cancer at an early, possibly curable stage.The company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250926999689/en/bioAffinity-Technologies-Adds-to-Growing-Number-of-Case-Studies-Demonstrating-Clinical-Value-of-CyPath-Lung">stated</a> that two potentially risky invasive procedures were avoided for patients facing difficult healthcare choices by using the test.CyPath Lung is a non-invasive test designed to enhance the early detection of lung cancer in patients at high risk for the disease. It uses advanced flow cytometry and artificial intelligence (AI) to identify cell populations in a patient’s sputum that indicate malignancy. In clinical studies, it was demonstrated that CyPath Lung had a sensitivity of 92%, specificity of 87%, and an accuracy of 88%.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BIAF">BIAF stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.BioAffinity stated that the three new cases were provided by a Texas pulmonologist who has been using the test for over a year. While early-stage lung cancer was diagnosed in 68-year-old Samuel with the help of the test, David avoided an unnecessary biopsy after the test came out negative. Lisa, with a previous diagnosis of lung cancer, proceeded with radiation therapy after a positive CyPath Lung result without performing a biopsy, as she might not have been healthy enough for the procedure.“We believe CyPath Lung can be a transformative tool in the lung cancer diagnostic pathway, especially when imaging results are inconclusive. A positive CyPath Lung result can lead to earlier diagnosis and treatment, and a negative result can spare patients from unnecessary invasive procedures,” Chief Medical Officer Gordon Downie said.BIAF stock is down 78% this year and by 90% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pharmaceutical-tariffs-a-light-at-the-end-of-the-trump-tunnel-for-big-pharma-says-jefferies/chDViCCR3e4">Pharmaceutical Tariffs ‘A Light At The End Of The Trump Tunnel’ For Big Pharma, Says Jefferies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

bioAffinity Technologies Stock Surged A Whopping 79% Today – Here’s An Important Update

The company reported that the use of its CyPath Lung test enabled the detection of lung cancer at an early stage.

Equity

The company reported that the use of its CyPath Lung test enabled the detection of lung cancer at an early stage.


BIAF Stock Down Following Q2 Earnings Despite CyPath Lung Growth

bioAffinity shifts its focus on CyPath Lung as the second-quarter 2025 loss widens, with rising adoption and new market expansion underway.

The Zacks Analyst Blog Highlights Meta Platforms, ServiceNow, Booking, Vaso and bioAffinity Technologies

META, NOW, and BKNG lead with AI-driven growth and digital transformation tailwinds, while VASO and BIAF offer speculative upside.

Top Research Reports for Meta Platforms, ServiceNow & Booking

META, NOW, and BKNG gain ground as AI, digital transformation, and global travel trends fuel top-line momentum.

BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline

U.S. stock markets spiraled lower last week as President Donald Trump's sweeping reciprocal tariffs rattled global investors.&nbsp;But while tech and industrials bore the brunt of the selloff, healthcare stocks showed surprising resilience — living up to their reputation as a defensive haven during periods of economic uncertainty.Here are three names from the sector that stood out&nbsp;with staggering weekly gains, offering retail traders on Stocktwits a rare dose of optimism in an otherwise chaotic week:iCoreConnect Inc (ICCT) - 1,579% weekly gain&nbsp;Ocoee, Florida-based iCoreConnect offers software-as-a-service for the healthcare market. Last week, there were no major news catalysts for the stock, although it has seen heavy trading volume since the beginning of April.&nbsp;On Stocktwits, sentiment remained 'extremely bullish' last week amid stunning gains, with followers jumping by 69% and message volume exploding by over 40,400%.&nbsp; &nbsp;<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/ICCT_sentiment_and_message_volume_as_of_April_6_png_16855887e8.webp" alt="ICCT sentiment and message volume as of April 6.png" width="1318" height="316"><figcaption>ICCT sentiment and message volume as of April 6. | source: Stocktwits</figcaption></figure>Recent posts suggest that retail traders anticipate a major development, though many dismissed the possibility of another equity offering —something the company has done multiple times.Last year, the company received the backing of several state dental associations for its cloud solutions and made some strategic acquisitions.BioAffinity Technologies Inc (BIAF) - 163% weekly gain&nbsp;San Antonio, Texas-based BioAffinity is a company focused on making products for the early detection of cancers. Its initial product, CyPath Lung, uses a patient's sputum and proprietary automated flow cytometry data analysis to diagnose early-stage lung cancer accurately.Last week, Maxim — the sole research firm covering the stock — downgraded BioAffinity to 'Hold' from 'Buy' after the company posted annual financial results.BioAffinity's 2024 revenue increased 270% from a year earlier, primarily due to the acquisition of Precision Pathology Laboratory Services (PPLS). However, the company's net loss also increased due to higher operating expenses.In March, BioAffinity said it expects to realize most of its planned $4 million in annual cost savings through workforce and operational cuts at PPLS and improving operational efficiency by cutting supply and service costs.&nbsp;<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/BIAF_sentiment_and_message_volume_as_of_April_6_png_0a9f433739.webp" alt="BIAF sentiment and message volume as of April 6.png" width="1318" height="316"><figcaption>BIAF sentiment and message volume as of April 6. | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment ended Friday higher in the 'extremely bullish' zone amid a 3,750% spike in weekly message volume.Alaunos Therapeutics Inc (TCRT) - 102% weekly gain&nbsp;Houston, Texas-based Alaunos is a biotech firm that also rocketed last week with virtually no major news catalysts, with Stocktwits sentiment flipping to 'extremely bullish' from 'neutral.'&nbsp;Regulatory filings from April 1 revealed that senior executives, including interim CEO Dale Curtis Hogue, exercised options to buy 7,000 shares at $1.46 apiece.&nbsp;The company's annual 10-K report also showed that Alaunos' 2024 revenue doubled to $10,000, while net loss shrank to $4.6 million from $35.1 million a year earlier.&nbsp;Alaunos significantly cut expenses by winding down clinical programs, such as its costly TCR-T clinical trial, and reducing headcount.&nbsp;The company is exploring strategic options such as mergers, partnerships, or asset sales.&nbsp;<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/TCRT_sentiment_and_message_volume_as_of_April_6_png_163e68145a.webp" alt="TCRT sentiment and message volume as of April 6.png" width="1318" height="316"><figcaption>TCRT sentiment and message volume as of April 6. | source: Stocktwits</figcaption></figure>Alaunos is now focused on its small molecule oral obesity drug program, which aims to offer a differentiated alternative to injectable GLP-1 therapies by preserving lean muscle mass.&nbsp;Alaunos regained Nasdaq compliance in February and expects its current cash reserves to last into the second quarter.For updates and corrections, email newsroom[at]stocktwits[dot]com.

These 3 Healthcare Stocks Show Serious Muscle Amid Trump Tariff Turmoil: Are Retail Traders Feeling Bullish?

iCoreConnect, BioAffinity and Alaunos Therapeutics posted strong gains last week amid heavy trading volume.

WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million WallachBeth Capital Announces Closing of bioAffinity...

bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) announced today it has closed its previously announced warrant exercise agreements with four existing accredited investors to exercise certain...

WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for...

bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) announced today it has entered into warrant exercise agreements with three existing accredited investors to exercise certain outstanding...

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

BIAF
BioAffinity Technologies Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BIAF News

BIAF BioAffinity Technologies Inc